PE20081315A1 - Derivados de benzimidazol como antagonistas de vr-1 - Google Patents

Derivados de benzimidazol como antagonistas de vr-1

Info

Publication number
PE20081315A1
PE20081315A1 PE2007001076A PE2007001076A PE20081315A1 PE 20081315 A1 PE20081315 A1 PE 20081315A1 PE 2007001076 A PE2007001076 A PE 2007001076A PE 2007001076 A PE2007001076 A PE 2007001076A PE 20081315 A1 PE20081315 A1 PE 20081315A1
Authority
PE
Peru
Prior art keywords
ethyl
halogen
methyl
antagonists
benzimidazole derivatives
Prior art date
Application number
PE2007001076A
Other languages
English (en)
Inventor
William L Brown
Shawn Johnstone
Denis Labrecque
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081315A1 publication Critical patent/PE20081315A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZIMIDAZOL DE FORMULA (I) DONDE R1 ES CN, HALOGENO, C(=)CH3; R2 ES METILO O H; R3 ES H O HALOGENO, R4 Y R5 SON INDEPENDIENTEMENTE METILO O ETILO, O JUNTOS AL ATOMO C AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO DE 3 A 6 MIEMBROS O HETEROCICLO DE 5 A 6 MIEMBROS; R6 Y R7 SON INDEPENDIENTEMENTE H, HALOGENO, METILO O ETILO. SON SELECCIONADOS: (S)(-)-2-(7-CIANO-1H-BENZIMIDAZOL-1-IL)-N-{1-[4-(1-CIANO-1-METILETIL)FENIL]ETIL}ACETAMIDA, (S)(-)-N-{1-[4-(1-CIANO-1-METILETIL)FENIL]ETIL}-2-(7-FLUORO-1H-BENZIMIDAZOL-1-IL)ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE VR1 (RECEPTOR VANILLOIDE 1) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR
PE2007001076A 2006-08-11 2007-08-10 Derivados de benzimidazol como antagonistas de vr-1 PE20081315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83724906P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
PE20081315A1 true PE20081315A1 (es) 2008-11-08

Family

ID=39033277

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001076A PE20081315A1 (es) 2006-08-11 2007-08-10 Derivados de benzimidazol como antagonistas de vr-1

Country Status (25)

Country Link
US (2) US7906654B2 (es)
EP (1) EP2051967B1 (es)
JP (1) JP5140077B2 (es)
KR (1) KR101412881B1 (es)
CN (2) CN101522637A (es)
AR (1) AR062299A1 (es)
AU (1) AU2007282186B2 (es)
BR (1) BRPI0715746B8 (es)
CA (1) CA2660529C (es)
CL (1) CL2007002343A1 (es)
CO (1) CO6150176A2 (es)
ES (1) ES2533971T3 (es)
IL (1) IL196672A0 (es)
MX (1) MX2009001496A (es)
MY (1) MY147649A (es)
NO (1) NO20091054L (es)
NZ (1) NZ575416A (es)
PE (1) PE20081315A1 (es)
RU (1) RU2458055C2 (es)
SG (1) SG173360A1 (es)
TW (1) TWI433839B (es)
UA (1) UA96764C2 (es)
UY (1) UY30533A1 (es)
WO (1) WO2008018827A1 (es)
ZA (1) ZA200900961B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AR058705A1 (es) 2005-12-23 2008-02-20 Astrazeneca Ab Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
ES2647585T3 (es) 2012-07-18 2017-12-22 Saint Louis University Derivados de aminoácido beta como antagonistas de integrina
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
BR112017011099B1 (pt) 2014-12-08 2021-10-13 Rohm And Haas Company Um aditivo de poliolefina, uma pololefina resistente à dobra e um método de preparação dos mesmos
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
AU2016381336A1 (en) 2015-12-30 2018-06-28 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
JP2022516362A (ja) * 2019-01-08 2022-02-25 ネオメド インスティテュート-インスティテュート ネオメド (s)-2-(7-シアノ-1h-ベンズイミダゾール-1イル)-n-{1-[4-(1-シアノ-1-メチルエチル)フェニル]エチル}アセトアミドの結晶形態
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
BE793718A (fr) 1972-01-07 1973-07-05 Merck & Co Inc Aminobenzimidazoles
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4738981A (en) * 1984-11-13 1988-04-19 Warner-Lambert Substituted trans-1,2-diaminocyclohexyl amide compounds
JP2639000B2 (ja) 1988-09-30 1997-08-06 スズキ株式会社 酸素富化エンジンの酸素富化空気制御装置
JPH0295767A (ja) 1988-09-30 1990-04-06 Showa Alum Corp 吸気マニホルド
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
WO1997024334A1 (fr) 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
OA12046A (en) 1999-08-12 2006-05-02 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents.
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
AU2001264566A1 (en) 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
WO2001096336A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2001278771A1 (en) 2000-08-22 2002-03-04 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
ITTO20010110A1 (it) 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
EA008476B1 (ru) 2001-06-11 2007-06-29 Биовитрум Аб Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii
US20040259875A1 (en) 2001-07-31 2004-12-23 Takeshi Yura Amine derivatives
JP4059473B2 (ja) 2001-08-09 2008-03-12 株式会社ルネサステクノロジ メモリカード及びメモリコントローラ
PE20030417A1 (es) 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CA2468544A1 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MXPA04012914A (es) 2002-06-20 2005-03-31 Biovitrum Ab Nuevos compuestos utiles para el tratamiento de la obesidad, diabetes tipo ii y desordenes cns.
FR2842069B1 (fr) 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE539077T1 (de) 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
EP1736465A4 (en) * 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
SE0402284D0 (sv) 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
AR058705A1 (es) 2005-12-23 2008-02-20 Astrazeneca Ab Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Also Published As

Publication number Publication date
US7906654B2 (en) 2011-03-15
US20080221188A1 (en) 2008-09-11
CA2660529C (en) 2014-10-21
IL196672A0 (en) 2009-11-18
MX2009001496A (es) 2009-02-18
KR20090035701A (ko) 2009-04-10
EP2051967A1 (en) 2009-04-29
TW200817338A (en) 2008-04-16
US8093402B2 (en) 2012-01-10
BRPI0715746A2 (pt) 2013-07-16
CA2660529A1 (en) 2008-02-14
NO20091054L (no) 2009-03-09
BRPI0715746B1 (pt) 2020-09-24
RU2009103675A (ru) 2010-09-20
ZA200900961B (en) 2010-07-28
CN101522637A (zh) 2009-09-02
CO6150176A2 (es) 2010-04-20
US20110137045A1 (en) 2011-06-09
WO2008018827A1 (en) 2008-02-14
JP2010500345A (ja) 2010-01-07
CN101792436A (zh) 2010-08-04
MY147649A (en) 2012-12-31
AU2007282186B2 (en) 2011-07-07
RU2458055C2 (ru) 2012-08-10
UY30533A1 (es) 2008-03-31
ES2533971T3 (es) 2015-04-16
NZ575416A (en) 2011-10-28
BRPI0715746B8 (pt) 2021-05-25
EP2051967A4 (en) 2011-06-29
EP2051967B1 (en) 2014-12-31
CL2007002343A1 (es) 2008-04-04
SG173360A1 (en) 2011-08-29
AU2007282186A1 (en) 2008-02-14
KR101412881B1 (ko) 2014-06-26
UA96764C2 (ru) 2011-12-12
JP5140077B2 (ja) 2013-02-06
TWI433839B (zh) 2014-04-11
WO2008018827A8 (en) 2009-02-19
AR062299A1 (es) 2008-10-29

Similar Documents

Publication Publication Date Title
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20131377A1 (es) Triazina-oxadiazoles
PE20120578A1 (es) Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20110684A1 (es) Agonistas de los receptores de la melanocortina
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
PE20080007A1 (es) Compuestos derivados de bencimidazolona que tienen actividad en el receptor m1
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
RS51137B (sr) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20140934A1 (es) Derivados de pirazol
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed